IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC).
用户slK1Kxicm8Dw
19天前
43
10
已关闭
DOI: 10.1200/jco.2021.39.3_suppl.267
文献链接: https://ascopubs.org/doi/10.1200/JCO.2021.39.3_suppl.267
其他信息:
出版社: American Society of Clinical Oncology (ASCO)
作者: Richard S. Finn; Shukui Qin; Masafumi Ikeda; Peter R. Galle; Michel Ducreux; Tae-You Kim; Ho Yeong Lim; Masatoshi Kudo; Valeriy Vladimirovich Breder; Philippe Merle; Ahmed Omar Kaseb; Daneng Li; Wendy Verret; Hui Shao; Juan Liu; Lindong Li; Andrew X. Zhu; Ann-Lii Cheng
